Krystal Biotech was founded by visionary leaders deeply rooted in biotechnology, scientific research, and pharmaceutical development, notably including Krish S. Krishnan and Suma Krishnan, who serves as the President of Research and Development. Their combined expertise in molecular biology, translational medicine, and corporate strategy laid the foundational groundwork for designing the proprietary, redosable gene therapy platform that defines the company today. By establishing the enterprise with a clear focus on addressing rare and difficult-to-treat diseases using engineered viral vectors, the founders created a unique infrastructure capable of taking treatments seamlessly from early-stage laboratory discovery through rigorous clinical trials to full global commercialization.